RCT

Pooled REVEAL trials of oxymetazoline cream (2018)

885 people across the two pivotal trials did better on oxymetazoline than on the cream base alone at day 29, and erythema did not meaningfully worsen in the 28 days after stopping.

Two identical trials were pooled, covering 885 people with moderate to severe lasting facial redness from rosacea. Everyone used either oxymetazoline 1% cream or the same cream without the drug, once a day for 29 days, then was followed for another 28 days. Significantly more people on the real cream improved by at least two grades on both the doctor's rating and their own. Side effects were uncommon, and redness did not meaningfully get worse after stopping in either group.

Stein-Gold L, Kircik L, Draelos ZD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. J Drugs Dermatol. 2018;17(11):1201-1208.